Журналов:     Статей:        

Рецепт. 2019; : 100-108

Хроническая крапивница: возможности контроля

Маслова Л. В.

Аннотация

Пациенты с хронической крапивницей испытывают значительный дискомфорт и нуждаются в эффективном лечении. Такому лечению предшествуют тщательный диагностический процесс, оценка активности, тяжести и контроля заболевания с применением хорошо установленных подходов. Затем лечение корректируют в соответствии с потребностями пациента и терапевтическим ответом, основываясь на принципе «так много, как необходимо, так мало, как возможно». После достижения контроля рекомендуется периодически предпринимать попытки отмены лекарственных препаратов, чтобы выявить спонтанную ремиссию заболевания. Хроническую крапивницу необходимо лечить до тех пор, пока не наступит спонтанная ремиссия.

Список литературы

1. Dona I. (2014) NSAID-induced urticaria/angioedema does not evolve into chronic urticaria: a 12-year follow-up study. Allergy, vol. 69, no 4, pp. 438-444.

2. Groffik A. (2011) Omalizumab - an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy, vol. 66, no 2, pp. 303-305.

3. Krause K. (2013) Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy, vol. 68, no 7, pp. 921-928.

4. Magerl S. (2016) The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA2LEN/EDF/UNEF consensus recommendations 2016 update and revision. Allergy, vol. 71, no 6, pp. 780-802.

5. Maurer M. (2018) Chronic urticaria - What does the new guideline tell us? JDDG, vol. 16, no 5, pp. 584-593.

6. Nurmatov U.B. (2015) H1-antihistamines for primary mast cell activation syndromes: a systematic review. Allergy, vol. 70, no 9, pp. 1052-1061.

7. Staubach P. (2016) Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy, vol. 71, no 8, pp. 1135-1144.

8. Tedeschi A. (2014) Chronic urticaria and coagulation: pathophysiological and clinical aspects trial. Allergy, vol. 69, no 6, pp. 683-691.

9. Zhong H. (2014) Chronic urticaria in Chinese population: a hospital-based multicenter epidemiological study. Allergy, vol. 69, no 3, pp. 1052-1061.

10. Zuberbier T. (2014) The EAACI/ GA2LEN/EDF/WAO Guideline for definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy, vol. 69, no 7, pp. 868-887.

11. Zuberbier T. (2018) The EAACI/ GA2LEN/EDF/WAO Guideline for definition, classification, diagnosis, and management of urticaria. Allergy, vol. 73, pp. 1393-1414.

Recipe. 2019; : 100-108

Chronic Urticaria: Control Capabilities

Maslova L. .

Abstract

Patients with chronic urticarial experience significant impairment and require an effective treatment. Such treatment is preceded by a thorough diagnostic workup and measurement of disease activity, disease burden and disease control using well established tools. Treatment is subsequently adjusted according to patient needs and therapeutic response, based on the tenet "as much as necessary, as little as possible". Once disease control has been achieved, it is recommended to make intermittent attempts at medication withdrawal in order to identify spontaneous disease remission. Chronic urticarial should be treated until spontaneous remission occurs.
References

1. Dona I. (2014) NSAID-induced urticaria/angioedema does not evolve into chronic urticaria: a 12-year follow-up study. Allergy, vol. 69, no 4, pp. 438-444.

2. Groffik A. (2011) Omalizumab - an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy, vol. 66, no 2, pp. 303-305.

3. Krause K. (2013) Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy, vol. 68, no 7, pp. 921-928.

4. Magerl S. (2016) The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA2LEN/EDF/UNEF consensus recommendations 2016 update and revision. Allergy, vol. 71, no 6, pp. 780-802.

5. Maurer M. (2018) Chronic urticaria - What does the new guideline tell us? JDDG, vol. 16, no 5, pp. 584-593.

6. Nurmatov U.B. (2015) H1-antihistamines for primary mast cell activation syndromes: a systematic review. Allergy, vol. 70, no 9, pp. 1052-1061.

7. Staubach P. (2016) Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy, vol. 71, no 8, pp. 1135-1144.

8. Tedeschi A. (2014) Chronic urticaria and coagulation: pathophysiological and clinical aspects trial. Allergy, vol. 69, no 6, pp. 683-691.

9. Zhong H. (2014) Chronic urticaria in Chinese population: a hospital-based multicenter epidemiological study. Allergy, vol. 69, no 3, pp. 1052-1061.

10. Zuberbier T. (2014) The EAACI/ GA2LEN/EDF/WAO Guideline for definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy, vol. 69, no 7, pp. 868-887.

11. Zuberbier T. (2018) The EAACI/ GA2LEN/EDF/WAO Guideline for definition, classification, diagnosis, and management of urticaria. Allergy, vol. 73, pp. 1393-1414.